Maulana Azad Medical College
New Delhi, National Capital Territory of Delhi, 110002, India
NCT Number: NCT03614273
The primary objective of this study was to compare the effectiveness of nebulized hypertonic saline (3%) and nebulized adrenaline in bronchiolitis. The secondary objective was to assess whether non-responders to initial therapy benefit from continuation of the same therapy.
This trial was conducted at a tertiary care teaching hospital over a period of one year in children with bronchiolitis presenting to the out-patient department and emergency. After obtaining a signed informed consent from the parents, all eligible children were assessed for baseline characteristics. A complete hemogram, chest X-ray were done in all and arterial blood gas analysis where ever required.
Computer generated random numbers were used for enrolment in consecutive manner and patients were randomly assigned into two groups. The first group received one dose (4ml) of nebulized hypertonic saline (3%).The second group received one dose (0.1 mg/kg) of nebulized adrenaline diluted in normal saline to make it a 4ml solution. Supportive care (nasal clearing, antipyretics, oxygenation, intravenous fluids) was done in both groups as necessary.
All children were reassessed 20 minutes after one dose of nebulization using the clinical score and a child was labelled as a "responder" if he showed an improvement in the clinical severity score by atleast 3 points after 20 minutes of nebulization. Both responders and non-responders were given a repeat dose of nebulization according to the group to which the child had been randomized, if: a) Severe audible wheeze with severe respiratory distress (severity score ≥9) b) Inability to maintain saturation >92% even on an O2 flow of 4 L/min. Non responders were given a maximum of three continuous doses of nebulization.
Child was considered fit for discharge if he/she was feeding well orally, there was no need for intravenous fluids, clinical severity score ≤3 and maintaining oxygen saturation >92% on room air for a period of more than 12 hours.
Looking for future studies?
Notify Me1 month–2 year
All sexes
Interventional
Not applicable
New Delhi, National Capital Territory of Delhi, 110002, India
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
Other names: Epinephrine
Time frame: During hospitalization, approximately 2 days
Duration from the time of enrolment to the point at which the discharge criteria (feeding well orally, no need for intravenous fluids, clinical severity score ≤ 3 and maintaining oxygen saturation >92% on room air for a period of more than 12 hours) are met.
Time frame: 20 minutes after the first nebulization
A decrease in the Wang bronchiolitis clinical severity score by at least 3 points after 20 minutes of nebulization was considered as an improvement in the clinical condition. The Wang score ranges from 0 - 12 [0-4: mild, 5-8: moderate, 9-12: severe].
Time frame: During hospitalization, approximately 2 days
Intravenous fluids were given to children unable to accept orally.
Time frame: Till the time the child maintained a saturation of more than 94% for at least 4 hours
Oxygen was administered when the saturation was less than 92%
Time frame: During hospitalization, approximately 2 days
Indications for repeat dose were if:
Time frame: Assessed 20 minutes after each nebulization
An improvement in the clinical severity score by at least 3 points after each nebulization.
Maulana Azad Medical College
Other
Nebulized Hypertonic Saline (3%) Versus Nebulized Adrenaline for Treatment of Bronchiolitis: A Randomized Control Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06932341
Bronchial Diseases, Bronchiolitis
St. Petersburg, Florida, United States
View Trial DetailsNCT06016244
Bronchial Diseases, Bronchial Hyperreactivity
Haarlem, North Holland, Netherlands
View Trial DetailsNCT02824744
Bronchial Diseases, Bronchiolitis
Montpellier, France
View Trial DetailsNCT03298217
Bronchial Diseases, Bronchiolitis
Montpellier, France
View Trial Details